Please login to the form below

Not currently logged in
Email:
Password:

legal action

This page shows the latest legal action news and features for those working in and with pharma, biotech and healthcare.

Still no ferry contracts for no-deal Brexit medicines supplies

Still no ferry contracts for no-deal Brexit medicines supplies

The rushed procurement process eventually cost the taxpayer £85m, including legal action from Eurotunnel, because it had not been considered in the tendering process.

Latest news

  • US states sue generic firms over ‘inflated’ prices US states sue generic firms over ‘inflated’ prices

    The legal action was filed on Friday by Connecticut Attorney General William Tong, and follows a five-year investigation into the alleged conspiracy to fix prices and allocate markets for more

  • Gilead gets 'gold' in England's hepatitis C eradication drive Gilead gets 'gold' in England's hepatitis C eradication drive

    However, it ran into trouble when AbbVie mounted a legal action against NHSE, accusing it of of not treating all bidders fairly. ... programmes. NHS England has said, however, that the legal action delayed its plans by six months, and is now reluctant to

  • Leadiant gets FDA OK for bubble boy disease drug Leadiant gets FDA OK for bubble boy disease drug

    A non-profit health advocacy group in the Netherlands has launched legal action against the Italian drugmaker (formerly Sigma-Tau), accusing it of hiking the price of chenodeoxycholic acid (CDCA)

  • ABPI bid to overturn NICE’s budget impact rules fails ABPI bid to overturn NICE’s budget impact rules fails

    The Association of the British Pharmaceutical Industry (ABPI) has been fighting a legal action to try to overturn NICE’s introduction of a £20m cost ceiling for new drugs that have ... NHS England said in a statement that the High Court “has

  • New EU and US approvals for Humira biosimilars New EU and US approvals for Humira biosimilars

    AbbVie is claiming patent protection for Humira in the US out to 2022 and has already taken legal action to try to keep both Amjevita and Cyltezo off the market. ... Thus far, Amgen has opted not to launch its biosimilar 'at-risk' but is waiting to see

More from news
Approximately 9 fully matching, plus 57 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

  • Article: The Colombia Conundrum

    Challenges. For treatments that fall outside of these schemes, there is an alternative route patients can go down to attempt to access them: legal action, via ‘recobros’. Given ‘right to healthcare’

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

Article: Like, Like, Like: Harnessing the power of social media insights
...
Its Know Your Numbers week
Do you know yours?...
What is changing in mental health and dementia care?
Paul Midgley, of Wilmington Healthcare, takes a look at the NHS Long Term Plan's bid to transform mental health and dementia services...

Infographics